3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
32
Observational
1
Expanded_access
1
Sponsor
Cancer Type
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Interventions
veliparib
2
leronlimab
2
sacituzumab govitecan
1
iniparib
1
Vinorelbine
1
Cisplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
Triple Negative Breast Neoplasms
×
sacituzumab govitecan
×
Clear all
NCT04320693
2021-08-19
Expanded Access for IMMU-132
Gilead Sciences
Approved for marketing